STEP 2
Financiado
Spatiotemporal regulation of T cell Priming
The initiation of adaptive cellular immunity requires antigen-specific interactions between Dendritic cells (DC) and naive CD8 T cells in secondary lymphoid organs. We aim to understand how the dynamic migratory behavior of myeloi...
The initiation of adaptive cellular immunity requires antigen-specific interactions between Dendritic cells (DC) and naive CD8 T cells in secondary lymphoid organs. We aim to understand how the dynamic migratory behavior of myeloid and lymphoid cells is coordinated to ensure that the right cells communicate at the right time in the right place to enable robust immune responses. Using intravital microscopy, we have recently identified a critical phase (Step 2) of T cell priming that follows the initial encounter of DC and CD8 T cells and is essential to develop protective immunity.
The aim of this proposal is to identify the cellular and molecular mechanisms regulating T cell differentiation during Step 2. We will employ a newly developed imaging method (Net-Vis) to investigate how key elements of Step 2 (XCR1 DC) receive antigenic and inflammatory information within a network of myeloid cells. Next, we will test a novel model of T cell priming in which stepwise relocalization to multicellular clusters within the LN orchestrates T cell differentiation. Combining deep-tissue intravital microscopy, Niche-seq and novel genetic approaches, we will identify the cellular players and molecules guiding these processes and test their mechanistic implications. Finally, we will investigate the identity and mechanisms of Foxp3+ T cells that co-regulate CD8 T cell activation and differentiation during Step 2.
In summary, we will exploit an array of innovative imaging, spatiotemporal transcriptomics and genetic approaches to investigate novel fundamental aspects of CD8 T cell priming during a newly discovered distinct phase of T cell activation and differentiation. Investigating the mechanisms that guide these central steps in adaptive immunity is anticipated to reveal new avenues for the therapeutic manipulation of immune responses against infection and cancer.
ver más
Duración del proyecto: 74 meses
Fecha Inicio: 2019-02-06
Fecha Fin: 2025-04-30
Fecha Fin: 2025-04-30
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2019-02-06
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
ERC-2018-COG:
ERC Consolidator Grant
Cerrada
hace 6 años
Presupuesto
El presupuesto total del proyecto asciende a
2M€
Líder del proyecto
JULIUSMAXIMILIANSUNIVERSITAT WURZBURG
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
545.13K€ |
Participante